Skip to main content

Miquel Vila Bover

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

Institutions of which they are part

Head of group
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Miquel Vila Bover

Institutions of which they are part

Head of group
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder.

In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN).

I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.

Projects

Mecanismos moleculares de neurodegeneración ligada a la neuromelanina en la enfermedad de Parkinson y envejecimiento cerebral

IP: Miquel Vila Bover
Collaborators: Thais Cuadros Arasa, Helena Xicoy Cortada, Marta González Sepúlveda, Annabelle Parent
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 332750
Reference: PID2020-116339RB-I00
Duration: 01/09/2021 - 31/08/2024

Ministerio de Ciencia

NIPARK - Targeting neuromelanin-linked neuronal dysfunction and degeneration in ageing and Parkinson’s disease using a combined imaging and brain stimulation approach

IP: Miquel Vila Bover
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: EC/ERANET_JNPD/2020/VILA
Duration: -

Sex-based modulation of neuromelanin-linked Parkinson’s disease pathology

IP: Miquel Vila Bover
Collaborators: Sex-based modulation of neuromelanin-linked Parkinson’s disease pathology
Funding agency: Michael J. Fox Foundation
Funding: 163538.22
Reference: SEX_NEUROMELANINE_MJFF2020
Duration: 01/02/2021 - 31/12/2024

ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE IMAGEN OPTICA

IP: Inmaculada Fuentes Camps
Collaborators: Ibane Abasolo Olaortua, Santiago Ramon y Cajal Agüeras, Miquel Vila Bover, Anna Meseguer Navarro, Joan Gavaldà Santapau, Francesc Bosch Albareda, Miguel Segura Ginard, Maria Nieves Martell Pérez-Alcalde, Victor Franco Puntes, Mª Jesús Cruz Carmona, Simon Schwartz Navarro, Joaquim Mateo Valderrama, Juan Angel Recio Conde, Anna Rosell Novel, Josep Roma Castanyer
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 134516.7
Reference: EQC2019-006306-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
SILVIA GARTNER TIZZANO

SILVIA GARTNER TIZZANO

Main researcher
Growth and Development
Read more
Luca Basile

Luca Basile

Administration and Management
Microbiology
Read more
Ana  Leon  Espitia

Ana Leon Espitia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.